Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34 + cells and T lymphocytes: Implications for the use of low viral doses and large-size vectors

Valeria Leuci, Giulia Mesiano, Loretta Gammaitoni, Cristina Cammarata, Sonia Capellero, Maja Todorovic, Noela Jordaney, Paola Circosta, Angela Elia, Marina Lesnikova, George E. Georges, Wanda Piacibello, Franca Fagioli, Alessandro Cignetti, Massimo Aglietta, Dario Sangiolo

Research output: Contribution to journalArticlepeer-review

Abstract

The proteasome system restricts lentiviral transduction of stem cells. We exploited proteasome inhibition as a strategy to enhance transduction of both hematopoietic stem cells (HSC) and T lymphocytes with low dose or large-size lentiviral vectors (LV). HSC showed higher transduction efficiency if transiently exposed to proteasome inhibitor MG132 (41.8% vs 10.7%, p

Original languageEnglish
Pages (from-to)218-226
Number of pages9
JournalJournal of Biotechnology
Volume156
Issue number3
DOIs
Publication statusPublished - Dec 10 2011

Keywords

  • Hematopoietic stem cells
  • Lentiviral transduction
  • T lymphocytes
  • Transduction efficiency

ASJC Scopus subject areas

  • Biotechnology
  • Applied Microbiology and Biotechnology

Fingerprint Dive into the research topics of 'Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34 + cells and T lymphocytes: Implications for the use of low viral doses and large-size vectors'. Together they form a unique fingerprint.

Cite this